CNMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Conmed Corp (CNMD) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock lacks clear positive catalysts, has mixed technical indicators, and recent financial performance shows declining net income and EPS despite revenue growth. Analysts have downgraded the stock, citing execution missteps and lack of identifiable catalysts. Given the current price trend and sentiment, it is better to hold off on buying this stock.
The MACD histogram is positive at 0.307, indicating a weak bullish signal, but it is contracting. RSI is neutral at 43.728, suggesting no clear trend. Moving averages are converging, and the stock is trading near its support level (S1: 36.806). Overall, the technical indicators do not provide a strong buy signal.
Revenue increased by 7.88% YoY in 2025/Q4, and gross margin improved by 2.02% YoY.
Analysts have downgraded the stock, citing execution missteps and lack of catalysts. No recent news or significant insider/hedge fund activity. Options data shows a high put-call ratio, indicating bearish sentiment.
In 2025/Q4, revenue increased to $373.2M (up 7.88% YoY), but net income dropped to $16.7M (down 50.41% YoY), and EPS fell to 0.54 (down 50.00% YoY). Gross margin improved slightly to 58.49% (up 2.02% YoY).
Recent analyst actions include a downgrade by Piper Sandler to Neutral from Overweight with a reduced price target of $39 (down from $55). Wells Fargo initiated coverage with an Equal Weight rating and a $42 price target. Analysts have expressed concerns over execution missteps and lack of catalysts.
